A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Carrageenan is a very common food additive in Western diets, but predictably causes inflammation in thousands of cell-based and animal experiments. OBJECTIVE: To assess the impact of carrageenan exposure on the interval to relapse in patients with ulcerative colitis in remission. METHODS: A randomized, double-blind, placebo-controlled, multicenter, clinical trial was conducted to assess if patients with ulcerative colitis in remission would have a longer interval to relapse if they followed a diet with no carrageenan. All participants were instructed in the no-carrageenan diet and were randomized to either placebo capsules or carrageenan-containing capsules. The carrageenan in the capsules was less than the average daily carrageenan intake from the diet. Relapse was defined as an increase of two or more points on the Simple Clinical Colitis Activity Index (SCCAI) and intensification of treatment for ulcerative colitis. Participants were followed by telephone calls every two weeks until relapse or one year of participation. The occurrence of relapse and inflammatory biomarkers were compared between the two groups. RESULTS: Twelve patients completed study questionnaires. Three patients who received carrageenan-containing capsules relapsed, and none of the patients who received placebo-containing capsules relapsed ( p = 0.046, log-rank test). Laboratory tests showed increases in Interleukin-6 ( p = 0.02, paired t-test, two-tailed) and fecal calprotectin ( p = 0.06; paired t-test, two-tailed) between the beginning and the end of study participation in the carrageenan-exposed group, but not in the placebo-group. CONCLUSION: Carrageenan intake contributed to earlier relapse in patients with ulcerative colitis in remission. Restriction of dietary carrageenan may benefit patients with ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Jowett, S. L., Seal, C. J., Pearce, M. S., Phillips, E., Gregory, W., Barton, J. R., & Welfare, M. R. (2004) · Gut · doi:10.1136/gut.2003.024828 · Cited by 462
Review of harmful gastrointestinal effects of carrageenan in animal experiments.
Tobacman, J. K. (2001) · Environmental Health Perspectives · doi:10.1289/ehp.01109983 · Cited by 370 · cited 1×
“Both low and high molecular weight carrageenan has been shown to cause intestinal inflammation [2].”
BackgroundSelf-citationClinical and Mucosal Improvement With Specific Carbohydrate Diet in Pediatric Crohn Disease
Cohen, S. A., Gold, B. D., Oliva, S., Lewis, J., Stallworth, A., Koch, B., Eshee, L., & Mason, D. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000449 · Cited by 235 · cited 1×
“This regimen has been shown to decrease intestinal inflammation by restoring the balance of bacteria within the gut and potentially resolving dysbiosis [57].”
BackgroundMarlow, G., Ellett, S., Ferguson, I. R., Zhu, S., Karunasinghe, N., Jesuthasan, A. C., Han, D. Y., Fraser, A. G., & Ferguson, L. R. (2013) · Human Genomics · doi:10.1186/1479-7364-7-24 · Cited by 200 · cited 14×
“The Mediterranean diet may also be effective in the management of IBD [58].”
BackgroundInfluentialFood additive carrageenan: Part II: A critical review of carrageenan in vivo safety studies
Weiner, M. L. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.861798 · Cited by 192 · cited 1×
“2 g/day in a 60 kg person (18–40 mg/kg day) was reported recently in an industry-sponsored study [29].”
Background
Cited by
Dietary guidance from the international organization for the study of inflammatory bowel diseases
Levine, A., Rhodes, J. M., Lindsay, J. O., Abreu, M. T., Kamm, M. A., Gibson, P. R., Gasche, C., Silverberg, M. S., Mahadevan, U., Boneh, R. S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.046 · Cited by 297
Ultra-processed foods and food additives in gut health and disease
Whelan, K., Bancil, A. S., Lindsay, J. O., & Chassaing, B. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00893-5 · Cited by 292
Barberio, B., Bertin, L., Facchin, S., Bonazzi, E., Cusano, S., Romanelli, G., Pesenti, F. F., Cazzaniga, E., Palestini, P., Zingone, F., et al. (2025) · Nutrients · doi:10.3390/nu17111879 · Cited by 28
Wellens, J., Vanderstappen, J., Hoekx, S., Vissers, E., Luppens, M., Van Elst, L., Lenfant, M., Raes, J., Derrien, M., Verstockt, B., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.005 · Cited by 17
Metadata
- Authors
- Bhattacharyya, S., Shumard, T., Xie, H., Dodda, A., Varady, K. A., Feferman, L., Halline, A. G., Goldstein, J. L., Hanauer, S. B., & Tobacman, J. K.
- Venue
- Nutrition and Healthy Aging
- Publisher
- SAGE Publications
- Published
- 2017-03-30
- Volume
- 4
- Issue
- 2
- Pages
- 181-192
- ISSN
- 2451-9480 (ISSN-L)
- 2451-9502
- OpenAlex
- W2604969316
- Cited by
- 128
- References
- 6
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.